Replies to post #231076 on Biotech Values

[DewDiligence]

VIR-2218 uses essentially the same RNAi modification as ABUS’ AB-729, according to Evaluate Vantage:

https://www.evaluate.com/vantage/articles/news/trial-results/vir-bids-enter-hepatitis-b-race

Reminder: ABUS’ share price crashed after reporting phase-1 data for AB-729 in late March (#msg-154597458, #msg-154612542), close to the low point of the broad market. Perhaps investors’ reaction would be more benign today.

Thanks for weighing in.

Disclosure: No position in ABUS or VIR; long ENTA.